Latest News

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes ©Crystal Light/stock.adobe.com
Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes

May 22nd 2024

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Dupilumab reduced annualized rate of exacerbations in COPD in NOTUS Surya P Bhatt, MD, MSPH Courtesy University of Alabama
Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight

May 21st 2024

Tezepelumab Reduces COPD Exacerbations, Improves Lung Function in Phase 2a COURSE Trial ©MichaelVi/stock.adobe.com
Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings

May 20th 2024

Budesonide-Based Triple Therapy Most Effective vs Dual Therapy for COPD / image credit Breztri Aeorsphere package couretesy of AstraZeneca
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPD

May 9th 2024

©Oleksandr/stock.adobe.com via AI
AstraZeneca at ATS 2024: Look for Late-Breaking Data on Novel Therapeutics for COPD

May 8th 2024

Latest CME Events & Activities

Surv.AI Says: Real-World Insights into the Journey for Patients with Pulmonary Arterial Hypertension

May 21, 2024

Register Now!

Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutatio...

May 21, 2024

Register Now!

Go To PER in Chicago

May 31, 2024 - June 2, 2024

Register Now!

The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward

View More

Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines

View More

Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board

View More

Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target

View More

25th Annual International Lung Cancer Congress®

July 25-27, 2024

Register Now!

24th Annual International Lung Cancer Congress®

View More

Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board

View More

Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC

View More

Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?

View More

Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care

View More

Community Practice Connections: 7th Annual School of Nursing Oncology™

View More

6th Annual Precision Medicine Symposium: An Illustrated Tumor Board

October 18-19, 2024

Register Now!

Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC

View More

6th Annual Advanced Practice Collaborative

View More

Community Practice Connections™: 24th Annual International Lung Cancer Congress®

View More

42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®

November 13-15, 2024

Register Now!

19th Annual New York Lung Cancers Symposium®

November 16, 2024

Register Now!

Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema

View More

Shaping the Management of COPD with Biologic Therapy

View More

Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care

View More

Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process

View More

How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities

View More

Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance

View More

© 2024 MJH Life Sciences

All rights reserved.